Tagged with M

Cyprus   Jacqueline Anastassiades has been involved in the development of the Cypriot healthcare sector for more than 10 years as the Managing Director of MSD. With the upcoming healthcare reforms, she brings her expert insights into the key requirements the Cyprus national health system should validate as well as the…

China Simon, you established Glory Medical back in 1998. What was the main rationale behind this significant decision? “We already have operations in Sri Lanka and Pakistan, and are exploring projects in Indonesia and Bangladesh, as well as in Latin America and the Middle East. Some of these places really need…

UK Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric one-stop-shop by deciding on smart investments, and why quality will always remain the key differentiation factor for a CDMO. In…

UK Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the affiliate the best performing in the coming years. She also details the strong heritage of Oncology and the affiliate’s exciting…

UK With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE, highlights what else makes the region special: its great talent, dedication to discovery and ability to build bridges between academia…

UK Thembalath Ramachandran, chairman and managing director of one of the UK’s fastest growing generics manufacturers, Bristol Laboratories, describes why he chose to relocate from India to start his business, the company’s significant manufacturing footprint in the UK, and how the British government could be doing more to support homegrown manufacturers.…

Turkey Bahadir Kaleagasi, secretary general of the Turkish Industry & Business Association (TÜSIAD) discusses the strengths of the country as Europe’s gateway to Asia in addition to the strong investment landscape the country still has. He comments that if all the key stakeholders add a “drop to the ocean of progress”…

UK Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on the big players in eyecare. Laboratoires Théa entered the UK for the first time back in 2007 via a joint…

UK Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential in driving forward early stage discovery. Louise Houson, Managing Director for the UK and Ireland explains the reasons for that…

Biogen After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field where research has met relentless challenges and a series of drug candidates have been unsuccessful. Indeed, the failure rate for Alzheimer’s drugs has been 99.6 percent over the…

Turkey Murat Üçer, reputed macroeconomist, former advisor to the Ministry of Economy, Global Source Partners’ consultant in Turkey, co-founder of Turkey Data Monitor, and senior lecturer at Koç University, dissects the dynamics driving the Turkish economy as well as the main risks that lie ahead. With a GDP growth of 7.4…

UK Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences investment: a historic focus on research and interest in clinical trials, great talent from world-class universities, as well as an…